Immune Thrombocytopenia Market Report 2026

The immune thrombocytopenia market size has grown strongly in recent years. It will grow from $3.61 billion in 2025 to $3.81 billion in 2026 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to improved understanding of autoimmune platelet disorders, increased availability of intravenous immunoglobulin therapy, rising diagnosis rates of chronic itp, advancements in hematology clinical practices, expansion of hospital-based hematology care.

The immune thrombocytopenia market size is expected to see strong growth in the next few years. It will grow to $4.72 billion in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to development of novel biologics and oral agents, growing focus on long-term disease management, increasing adoption of outpatient and home-based care, expansion of precision medicine in autoimmune disorders, rising healthcare access in emerging markets. Major trends in the forecast period include increasing adoption of targeted immunotherapies, growing use of thrombopoietin receptor agonists, rising focus on personalized treatment approaches, expansion of chronic itp management strategies, increasing awareness and early diagnosis of itp.

The rising prevalence of autoimmune diseases is expected to drive growth in the immune thrombocytopenia market in the coming years. Autoimmune diseases occur when the immune system mistakenly attacks healthy cells and tissues, causing inflammation and organ or system damage. Factors contributing to this rise include genetic predisposition, environmental influences, lifestyle changes, and increased awareness leading to better diagnosis. In the case of immune thrombocytopenia, autoimmune reactions trigger the destruction of platelets or impair their production in the bone marrow. For example, in November 2023, the Multiple Sclerosis International Federation (MSIF), a UK-based nonprofit, reported that approximately 2.9 million people worldwide were living with multiple sclerosis, an autoimmune disease, in 2023. Therefore, the increasing prevalence of autoimmune diseases is driving the immune thrombocytopenia market.

Key companies in the market are focusing on therapeutic innovations, especially intravenous (IV) therapies, to improve treatment outcomes, speed of response, patient adherence, and address unmet needs in thrombocytopenia management. IV therapy delivers medications, fluids, or nutrients directly into a patient’s vein through an IV line. For instance, in March 2024, Argenx SE, a Netherlands-based biotechnology company, announced that the Japan Ministry of Health, Labor, and Welfare approved VYVGART for intravenous administration in adults with primary immune thrombocytopenia (ITP). This approval represents a significant advancement, offering a targeted, rapid-acting approach that maintains platelet levels and addresses critical unmet needs in autoimmune disease management.

In December 2024, Keros Therapeutics Inc., a US-based biopharmaceutical company, partnered with Takeda Pharmaceutical Industries Ltd., a Japan-based biopharmaceutical firm, to develop and commercialize elritercept. This therapy targets disorders associated with dysfunctional TGF-β signaling, including thrombocytopenia and other rare diseases, further strengthening the market pipeline for innovative treatments.

Major companies operating in the immune thrombocytopenia market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Novartis AG, Amgen Inc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Intas Pharmaceuticals Ltd., CSL Behring, Grifols, UCB Pharma, Kyowa Kirin, Sobi (Swedish Orphan Biovitrum), 3SBio Inc., Biotest AG, Shionogi & Co. Ltd., Ligand Pharmaceuticals, Rigel Pharmaceuticals, Symphogen, Hansa Biopharma, Argenx.

North America was the largest region in the immune thrombocytopenia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immune thrombocytopenia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the immune thrombocytopenia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the immune thrombocytopenia market by increasing costs of imported biologics, plasma-derived products, and active pharmaceutical ingredients used in immunoglobulin and immunosuppressive therapies. These effects are more pronounced in regions dependent on imported specialty drugs, including parts of Asia-Pacific and Latin America. However, tariffs are also encouraging domestic manufacturing of biologics and strengthening local supply chains, which may improve long-term treatment availability and cost stability.

The immune thrombocytopenia market research report is one of a series of new reports that provides immune thrombocytopenia market statistics, including immune thrombocytopenia industry global market size, regional shares, competitors with a immune thrombocytopenia market share, detailed immune thrombocytopenia market segments, market trends and opportunities, and any further data you may need to thrive in the immune thrombocytopenia industry. This immune thrombocytopenia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Immune thrombocytopenia is a rare autoimmune bleeding disorder in which the immune system mistakenly attacks and destroys platelets, essential components for blood clotting. This results in a reduced platelet count, impairing the blood’s ability to form clots. Common symptoms include easy bruising, bleeding, and a rash of small red spots.

The primary types of immune thrombocytopenia include primary immune thrombocytopenia (ITP), secondary immune thrombocytopenia, and acquired immune thrombocytopenia. Primary ITP occurs when the immune system erroneously targets platelets in the blood. Treatment options include intravenous immunoglobulin, thrombopoietin receptor agonists, and immunosuppressive therapies, which are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The immune thrombocytopenia market consists of revenues earned by entities by providing services such as blood or platelet transfusions, splenectomy, plasma exchange, monitoring, and support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The immune thrombocytopenia market also includes sales of pharmaceutical drugs, diagnostic kits and reagents, medical devices, platelet transfusion products, and supportive care products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.